Amedisys Inc - Common Stock (AMED)

President Trump has spoken about implementing a family caregiver tax credit during his presidential campaign to ease the burden on caregivers, here's who gains.

UnitedHealth shares a quarterly report for the first time since the death of insurance unit leader Brian Thompson. A look at the estimates and key items to watch.

Amedisys and UnitedHealth extend their $3.3B merger deadline to 2025, amid DOJ scrutiny over competition concerns in the home health market.

AMEDISYS INC (NASDAQ:AMED) may be suited for quality investing, we'll explore why in this article.

UnitedHealth shares have declined 5.3% over the past week. The company faces a significant legal challenge to its $3.3 billion acquisition of Amedisys.

An aging U.S. population is increasing demand for home health care. The Optum-Amedisys merger, with divestitures to VitalCaring, aims to balance growth and competition.

UnitedHealth Group Inc (NYSE:UNH) shares are trading lower Tuesday. The U.S. Justice Department is moving to block the company's multi-billion acquisition of Amedisys Inc (NASDAQ:AMED).

AMED stock results show that Amedisys beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

AMED stock results show that Amedisys beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

It's not just enough for a company to pay a dividend, investors should look for dividend growth stocks that can continue to pay.

There are a few simple rules for investing for 10x returns but they are among the most difficult to follow.

These long-term care stocks provide older Americans with the care they need and the income to pay for it well into retirement.

The best stock picks for this week have long-term aims such as high earnings and growth for your portfolio.

The nation's largest health insurer has seen its shares fall despite a strong start to the year.

Morgan Stanley cut the price target for ArcBest Corporation (NASDAQ: ARCB) from $136 to $125. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. ArcBest shares fell 3.3% to close at $95.42 on Wednesday.